Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia

Basit Salik; Hangyu Yi; Nunki Hassan; Nancy Santiappillai; Binje Vick; Patrick Connerty; Alastair Duly; Toby Trahair; Andrew J Woo; Dominik Beck; Tao Liu; Karsten Spiekermann; Irmela Jeremias; Jianlong Wang; Maria Kavallaris; Michelle Haber; Murray D Norris; Dan A Liebermann; Richard J D'Andrea; Christopher Murriel; Jenny Y Wang

doi:10.1016/j.ccell.2020.05.014

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia

Basit Salik, Hangyu Yi, Nunki Hassan, Nancy Santiappillai, Binje Vick, Patrick Connerty, Alastair Duly, Toby Trahair, Andrew J Woo, Dominik Beck, Tao Liu, Karsten Spiekermann, Irmela Jeremias, Jianlong Wang, Maria Kavallaris, Michelle Haber, Murray D Norris, Dan A Liebermann, Richard J D'Andrea, Christopher MurrielJenny Y Wang

UWA Centre for Medical Research

Research output: Contribution to journal › Article

Abstract

Signals driving aberrant self-renewal in the heterogeneous leukemia stem cell (LSC) pool determine aggressiveness of acute myeloid leukemia (AML). We report that a positive modulator of canonical WNT signaling pathway, RSPO-LGR4, upregulates key self-renewal genes and is essential for LSC self-renewal in a subset of AML. RSPO2/3 serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts. RSPO receptor, LGR4, is epigenetically upregulated and works through cooperation with HOXA9, a poor prognostic predictor. Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia.

Original language	English
Journal	Cancer Cell
DOIs	https://doi.org/10.1016/j.ccell.2020.05.014
Publication status	E-pub ahead of print - 1 Jun 2020

Access to Document

10.1016/j.ccell.2020.05.014

Fingerprint Dive into the research topics of 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this

Salik, B., Yi, H., Hassan, N., Santiappillai, N., Vick, B., Connerty, P., Duly, A., Trahair, T., Woo, A. J., Beck, D., Liu, T., Spiekermann, K., Jeremias, I., Wang, J., Kavallaris, M., Haber, M., Norris, M. D., Liebermann, D. A., D'Andrea, R. J., ... Wang, J. Y. (2020). Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.05.014

Salik, Basit ; Yi, Hangyu ; Hassan, Nunki ; Santiappillai, Nancy ; Vick, Binje ; Connerty, Patrick ; Duly, Alastair ; Trahair, Toby ; Woo, Andrew J ; Beck, Dominik ; Liu, Tao ; Spiekermann, Karsten ; Jeremias, Irmela ; Wang, Jianlong ; Kavallaris, Maria ; Haber, Michelle ; Norris, Murray D ; Liebermann, Dan A ; D'Andrea, Richard J ; Murriel, Christopher ; Wang, Jenny Y. / Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. In: Cancer Cell. 2020.

@article{34b33b60582b4bce8479acaeeee7358a,

title = "Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia",

abstract = "Signals driving aberrant self-renewal in the heterogeneous leukemia stem cell (LSC) pool determine aggressiveness of acute myeloid leukemia (AML). We report that a positive modulator of canonical WNT signaling pathway, RSPO-LGR4, upregulates key self-renewal genes and is essential for LSC self-renewal in a subset of AML. RSPO2/3 serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts. RSPO receptor, LGR4, is epigenetically upregulated and works through cooperation with HOXA9, a poor prognostic predictor. Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia.",

author = "Basit Salik and Hangyu Yi and Nunki Hassan and Nancy Santiappillai and Binje Vick and Patrick Connerty and Alastair Duly and Toby Trahair and Woo, {Andrew J} and Dominik Beck and Tao Liu and Karsten Spiekermann and Irmela Jeremias and Jianlong Wang and Maria Kavallaris and Michelle Haber and Norris, {Murray D} and Liebermann, {Dan A} and D'Andrea, {Richard J} and Christopher Murriel and Wang, {Jenny Y}",

year = "2020",

month = jun,

day = "1",

doi = "10.1016/j.ccell.2020.05.014",

language = "English",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

}

Salik, B, Yi, H, Hassan, N, Santiappillai, N, Vick, B, Connerty, P, Duly, A, Trahair, T, Woo, AJ, Beck, D, Liu, T, Spiekermann, K, Jeremias, I, Wang, J, Kavallaris, M, Haber, M, Norris, MD, Liebermann, DA, D'Andrea, RJ, Murriel, C & Wang, JY 2020, 'Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia', Cancer Cell. https://doi.org/10.1016/j.ccell.2020.05.014

Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia. / Salik, Basit; Yi, Hangyu; Hassan, Nunki; Santiappillai, Nancy; Vick, Binje; Connerty, Patrick; Duly, Alastair; Trahair, Toby; Woo, Andrew J; Beck, Dominik; Liu, Tao; Spiekermann, Karsten; Jeremias, Irmela; Wang, Jianlong; Kavallaris, Maria; Haber, Michelle; Norris, Murray D; Liebermann, Dan A; D'Andrea, Richard J; Murriel, Christopher; Wang, Jenny Y.

In: Cancer Cell, 01.06.2020.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Targeting RSPO3-LGR4 Signaling for Leukemia Stem Cell Eradication in Acute Myeloid Leukemia

AU - Salik, Basit

AU - Yi, Hangyu

AU - Hassan, Nunki

AU - Santiappillai, Nancy

AU - Vick, Binje

AU - Connerty, Patrick

AU - Duly, Alastair

AU - Trahair, Toby

AU - Woo, Andrew J

AU - Beck, Dominik

AU - Liu, Tao

AU - Spiekermann, Karsten

AU - Jeremias, Irmela

AU - Wang, Jianlong

AU - Kavallaris, Maria

AU - Haber, Michelle

AU - Norris, Murray D

AU - Liebermann, Dan A

AU - D'Andrea, Richard J

AU - Murriel, Christopher

AU - Wang, Jenny Y

PY - 2020/6/1

Y1 - 2020/6/1

N2 - Signals driving aberrant self-renewal in the heterogeneous leukemia stem cell (LSC) pool determine aggressiveness of acute myeloid leukemia (AML). We report that a positive modulator of canonical WNT signaling pathway, RSPO-LGR4, upregulates key self-renewal genes and is essential for LSC self-renewal in a subset of AML. RSPO2/3 serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts. RSPO receptor, LGR4, is epigenetically upregulated and works through cooperation with HOXA9, a poor prognostic predictor. Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia.

AB - Signals driving aberrant self-renewal in the heterogeneous leukemia stem cell (LSC) pool determine aggressiveness of acute myeloid leukemia (AML). We report that a positive modulator of canonical WNT signaling pathway, RSPO-LGR4, upregulates key self-renewal genes and is essential for LSC self-renewal in a subset of AML. RSPO2/3 serve as stem cell growth factors to block differentiation and promote proliferation of primary AML patient blasts. RSPO receptor, LGR4, is epigenetically upregulated and works through cooperation with HOXA9, a poor prognostic predictor. Blocking the RSPO3-LGR4 interaction by clinical-grade anti-RSPO3 antibody (OMP-131R10/rosmantuzumab) impairs self-renewal and induces differentiation in AML patient-derived xenografts but does not affect normal hematopoietic stem cells, providing a therapeutic opportunity for HOXA9-dependent leukemia.

U2 - 10.1016/j.ccell.2020.05.014

DO - 10.1016/j.ccell.2020.05.014

M3 - Article

C2 - 32559496

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

ER -